'On standalone basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Supriya Lifescience has declined 9.69% to Rs 145.07 crore. Operating profit margin has declined from 38.94% to 35.64%, leading to 17.35% decline in operating profit to Rs 51.70 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 33.22% to 27.87%. Employee cost increased from 11.97% to 14.45%. Other expenses rose from 17.53% to 24.77%.
Other income up 20.27% to Rs 2.67 crore. PBIDT fell 16.06% to Rs 54.37 crore. Provision for interest up 50% to Rs 0.51 crore.
PBDT fell 16.41% to Rs 53.86 crore. Provision for depreciation rose 38.41% to Rs 6.45 crore.
Profit before tax down 20.68% to Rs 47.41 crore. Provision for tax was expense of Rs 12.62 crore, compa...
Pleaselogin & subscribe to view the full report.
More Reports
|
|